For Urovant, beating placebo in a pivotal trial of vibegron was the easy part.
Another vast trial is on the cards for Apple’s ECG, and ought to yield more meaningful data.
The long overdue readout of a pivotal birch pollen allergy vaccine trial draws a blank for the beleaguered UK company.
Axovant is the latest company to benefit from excitement over gene therapy data in small numbers of patients.
The failure of one of Allergan’s key pipeline projects puts the group’s chief executive under even more pressure.
Alnylam looks likely to get approval for its second RNAi candidate, givosiran. But toxicity issues have tainted the Envision trial win.
Shares in the company surge after its weekly growth hormone treatment proves superior to daily injections, raising broader hopes for Ascendis’s long-acting technology.
As doubts grow about targeting the folate receptor, Immunogen’s decision to press on with mirvetuximab soravtansine looks desperate.
Guardant gets a liquid biopsy trial win, but if it wants to drive sales it must get cancer societies on board.